.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
QuintilesIMS
Accenture
McKinsey
Julphar
Daiichi Sankyo
Deloitte
Cipla
Cerilliant

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,957,922

« Back to Dashboard

Summary for Patent: 4,957,922

Title: Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-di-hydro-4-oxo-7-(1-piperazinyl)-quinoline-3- carboxylic acid
Abstract:An aqueous infusion solution containing 0.015 to 0.5 g of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-car box ylic acid per 100 ml of aqueous solution and an amount of at least one physiologically tolerated acid which suffices to dissolve the active compound.
Inventor(s): Lammens; Robert F. (Leverkusen, DE), Mahler; Hans F. (Colonge, DE), Serno; Peter (Colonge, DE)
Assignee: Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:07/329,922
Patent Claim Types:
see list of patent claims
Formulation; Compound;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,957,922

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany3537761Oct 24, 1985

International Patent Family for Patent: 4,957,922

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus1729► Subscribe
German Democratic Republic252125► Subscribe
Germany3537761► Subscribe
Germany3676158► Subscribe
Denmark507886► Subscribe
Denmark175494► Subscribe
European Patent Office0219784► Subscribe
Finland864272► Subscribe
Finland84555► Subscribe
Greece3002544► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Julphar
McKesson
Federal Trade Commission
Fuji
Argus Health
Teva
Covington
Mallinckrodt
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot